GlassScriptPhysician profile
Bhupinder Chatrath
NPI 1023082088
$23,310.86
in general payments reported to CMS, 2019-2025
73 companies · $409 in 2025
The $409 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,111 · 2020: $2,404 · 2021: $3,349 · 2022: $4,389 · 2023: $6,213 · 2024: $2,435 · 2025: $409.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,372 · Education: $686.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,371.94 |
| Education | $685.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,960.58 | 2019-2025 | Tagrisso, Calquence, Enhertu |
| Novartis Pharmaceuticals Corporation | $1,497.37 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,479.93 | 2019-2024 | Opdivo, Opdualag |
| Exelixis INC. | $1,416.45 | 2019-2025 | Cabometyx |
| Janssen Biotech, INC. | $1,414.46 | 2019-2025 | Tecvayli, Darzalex, Imbruvica |
| Amgen INC. | $1,008.96 | 2019-2023 | Blincyto, Kyprolis, Xgeva |
| Astellas Pharma US INC | $915.83 | 2019-2025 | Xospata, Vyloy, Padcev |
| Merck Sharp & Dohme LLC | $876.95 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Glaxosmithkline, LLC. | $856.53 | 2019-2024 | Zejula, Jemperli, Ojjaara |
| Pfizer INC. | $788.68 | 2019-2024 | |
| Genentech USA, INC. | $756.17 | 2019-2025 | Polivy, Lunsumio, Phesgo |
| Daiichi Sankyo INC. | $745.39 | 2020-2024 | Enhertu, Injectafer |
| Eisai INC. | $698.66 | 2019-2024 | |
| Seagen INC. | $666.75 | 2019-2023 | Adcetris, Tukysa, Padcev |
| Genzyme Corporation | $598.79 | 2019-2024 |
Show all 73 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $598.28 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Takeda Pharmaceuticals U.S.A., INC. | $466.44 | 2019-2024 | Fruzaqla, Iclusig, Alunbrig |
| Incyte Corporation | $457.66 | 2019-2025 | Monjuvi, Jakafi |
| Abbvie INC. | $381.77 | 2019-2024 | Venclexta |
| Bayer Healthcare Pharmaceuticals INC. | $366.44 | 2019-2023 | |
| Lilly USA, LLC | $351.73 | 2019-2024 | Verzenio, Retevmo, Jaypirca |
| Sobi, INC | $351.08 | 2022-2024 | |
| Alexion Pharmaceuticals, INC. | $315.57 | 2019-2023 | Ultomiris |
| Pharmacyclics LLC, An Abbvie Company | $290.45 | 2019-2022 | |
| Stemline Therapeutics INC. | $272.66 | 2019-2023 | Orserdu |
| Morphosys, US INC. | $252.37 | 2021-2022 | |
| Array Biopharma INC | $206.44 | 2020-2025 | Lorbrena, Mektovi, Xalkori |
| Puma Biotechnology, INC. | $205.19 | 2019-2023 | |
| Ipsen Biopharmaceuticals, INC | $196.12 | 2022-2024 | Onivyde, Tazverik, Somatuline Depot |
| Coherus Oncology, INC. | $194.56 | 2021-2024 | |
| Apellis Pharmaceuticals, INC. | $183.40 | 2023-2024 | Empaveli |
| Emd Serono, INC. | $171.22 | 2019-2024 | Bavencio |
| Tersera Therapeutics LLC | $163.73 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $150.83 | 2019-2024 | Libtayo |
| Aveo Pharmaceuticals, INC. | $145.62 | 2021-2023 | Fotivda |
| Tesaro, INC. | $143.44 | 2019 | |
| Kite Pharma, INC. | $143.28 | 2020-2023 | Yescarta |
| Karyopharm Therapeutics INC. | $141.75 | 2020-2023 | Xpovio |
| Gilead Sciences, INC. | $125.90 | 2019-2024 | |
| Beigene USA, INC. | $125.82 | 2021-2023 | Brukinsa |
| Taiho Oncology, INC. | $109.04 | 2022-2024 | |
| Dova Pharmaceuticals | $105.30 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $87.16 | 2019-2020 | |
| Blueprint Medicines Corporation | $84.59 | 2021-2024 | Ayvakit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.16 | 2023-2024 | Gilotrif |
| Rigel Pharmaceuticals, INC. | $59.93 | 2022-2023 | Rezlidhia, Tavalisse |
| Deciphera Pharmaceuticals INC. | $57.51 | 2022-2024 | Qinlock |
| Jazz Pharmaceuticals INC. | $51.47 | 2019-2024 | |
| Mirati Therapeutics, INC. | $49.60 | 2023 | Krazati |
| Myriad Genetic Laboratories, INC. | $43.76 | 2022 | |
| Cti Biopharma Corp. | $34.55 | 2022-2023 | Vonjo |
| Octapharma USA, INC. | $34.12 | 2019 | |
| Mayne Pharma Commercial LLC | $33.87 | 2022 | |
| Pharmaessentia USA Corporation | $31.69 | 2024 | Besremi |
| Immunogen, INC. | $29.20 | 2024 | Elahere |
| Acrotech Biopharma INC. | $27.02 | 2021 | |
| Janssen Pharmaceuticals, INC | $25.67 | 2019-2022 | |
| Medtronic, INC. | $25.43 | 2024 | Osteocool Rf Ablation System |
| Clovis Oncology, INC. | $24.48 | 2019-2021 | |
| Azurity Pharmaceuticals, INC. | $21.38 | 2024 | Triptodur |
| Pharmacosmos Therapeutics INC. | $21.38 | 2023 | Monoferric |
| Blue Earth Diagnostics | $21.17 | 2022 | |
| Fresenius Kabi USA, LLC | $20.11 | 2023 | Stimufend |
| Adc Therapeutics America, INC. | $18.74 | 2023 | |
| Myovant Sciences INC. | $18.60 | 2022 | |
| Springworks Therapeutics, INC. | $18.27 | 2024 | Ogsiveo |
| Eusa Pharma (US) LLC | $18.25 | 2022 | |
| Recordati_rare_diseases_inc. | $18.10 | 2023 | Sylvant |
| Dendreon Pharmaceuticals LLC | $17.27 | 2019 | |
| Servier Pharmaceuticals LLC | $17.03 | 2023 | |
| Secura Bio, INC. | $14.20 | 2020 | |
| Btg International INC. | $13.92 | 2021 | |
| Epizyme, INC. | $11.64 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bhupinder Chatrath listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.